VivoSeq
Other

Hormone Receptor Positive

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Hormone Receptor Positive is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed5 · 83%
Active, not recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative
Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04842617·5,274 enrolled
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy
Completed·SSOLTI Breast Cancer Research Group·Phase 1·NCT04130152·22 enrolled
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Completed·GGBG Forschungs GmbH·Phase 3·NCT01864746·1,250 enrolled
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01197170·277 enrolled
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT01273168·40 enrolled
Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Completed·—·Phase 2·NCT03870399·23 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)